Unexpected finding could offer new treatment targets for meth addiction
An MBI research team made a preclinical discovery paving the way to test immune-modulating medicines as a tool to break the cycle of meth addiction.
An MBI research team made a preclinical discovery paving the way to test immune-modulating medicines as a tool to break the cycle of meth addiction.
Drs. Nancy Padilla-Coreano and Freddyson Martínez-Rivera published a review in the journal Pharmacological Reviews.
Study provides insight into how drug molecules may bind to dopamine D1 receptors.
Habibeh Khoshbouei, Pharm.D., Ph.D., associate professor of neuroscience in the MBI, explains her research into dopamine, a neurotransmitter involved in many brain-related functions.